Published on 7 October 2021
Description:
Time for pharma to ditch its cautious approach to creativity in comms, Alzheimer’s disease and beyond, Amarin is rethinking cardiovascular risk
Categories:
Pharmaceutical Market EuropePreview:
29 articles from this collection:
PME October 2021
2- 90TEN
3 - Comment
4 - PMEA 2021
5 - Contents
6-7 - News
6-7 - PME - Pharma Market Europe Pharmaceutical News
8-9 - News
10-11 - Coronavirus news
12 - Darwin’s medicine
12 - Pharma Market Europe Darwin’s medicine
13 - Rohit Khanna - Policy and Public Health
The technology responses to this pandemic have fallen far short of expectations
14 - Mike Dixon
15 - Maxine Smith
16-17 - Alzheimer’s disease and beyond
18-19 - he future of new medicine development and first-in-human studies
18-19 - Empowering patients empowers results
20-21 - Following the science in respiratory medicine
22-23 - Embracing virtual patient care
24 - Across Health & NHS news
26-28 - Curb your conservatism
29 - Ashfield MedComms
30 - Purple Agency
31 - PMLive
32-33 - beyond the bubble
34-35 - Mastering knowledge
36-37 - Graduate Programme
38-40 - Appointments
41 - Healthcare Comms News
42 - Q&A with Stephen Page
43 - Recruitment
43 - Pharma Market Europe (PME) Recruitment
44 - T40
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services